Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T
Idayat Akinola(Medical College of Wisconsin), Kathryn E. Flynn(Medical College of Wisconsin), Vamsi Bollu(Novartis (United States)), Bronwen E. Shaw(Royal Marsden NHS Foundation Trust), Marcelo C. Pasquini(Cleveland Clinic), Mimi Tesfaye(Novartis (United States)), Anand A. Dalal(Novartis (United States)), Rachel Cusatis(Medical College of Wisconsin)
Cited by 20
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
|New England Journal of Medicine|2022|457
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441
One million haemopoietic stem-cell transplants: a retrospective observational study
|The Lancet Haematology|2015|434